Roche Bets $100M on Unproven ALK7 RNAi: Novel Biology, Zero Clinical Data

Roche Secures RNAi Obesity Drug from Rona in $1B Deal

Roche has signed a licensing deal with China-based Rona Therapeutics for an experimental RNA interference medicine targeting the ALK7 protein for obesity. Under the terms, Roche will pay Rona $100 million upfront, with potential milestone and royalty payments that could exceed $1 billion. This agreement marks Roche's fifth deal with a Chinese drugmaker since late August and its tenth since early 2025, underscoring its aggressive strategy to build a significant presence in the competitive obesity drug market. The ALK7-targeting drug will join five other experimental obesity medicines in Roche's pipeline, complementing its existing incretin-based therapies.

• Roche's deal with Rona Therapeutics involves an upfront payment of $100 million, with Rona eligible for over $1 billion in total payments, including development, regulatory, and commercial milestones, plus sales royalties. This transaction is Roche's fifth with a China-based drugmaker since August and its tenth since the beginning of 2025, highlighting its strategic focus on partnerships in the region to expand its pipeline.
• The licensed drug is an RNA interference medicine designed to target ALK7, a cell surface receptor predominantly expressed in fat tissue that regulates lipid metabolism. Research indicates that individuals with reduced ALK7 activity exhibit favorable fat distribution and metabolic phenotypes, making the silencing of ALK7 expression a promising approach for addressing obesity, particularly by lowering levels of visceral fat.
• This ALK7-targeting therapy diversifies Roche's growing obesity pipeline, which already includes incretin drugs acquired from Carmot Therapeutics in 2023 and a licensing pact with Zealand Pharma. The move positions Roche to explore combination therapies, as several other companies, including GSK, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Wave Life Sciences, are also developing ALK7-targeting agents, indicating a competitive and evolving research area.

Addressing Persistent Limitations in Obesity Treatment

Obesity management remains one of the most clinically complex challenges in modern medicine, with no single treatment modality offering a durable, universally effective solution. Current approaches — ranging from lifestyle intervention and pharmacotherapy to bariatric surgery — each carry distinct limitations that constrain long-term outcomes across patient populations.

• Weight regain following pharmacotherapy discontinuation. Randomized and real-world data consistently demonstrate substantial weight regain after GLP-1 receptor agonist cessation. The STEP 1 trial extension showed that semaglutide and placebo participants regained 11.6 and 1.9 percentage points of lost weight, respectively, by week 120, resulting in a net loss of only 5.6% from baseline for the semaglutide group. Real-world data indicate that up to 65% of users discontinue GLP-1 RAs within a year of initiation, and randomized controlled trials demonstrate that two-thirds of lost weight is typically regained within a year of discontinuation. Post-cessation weight regain averages 5.6 kg within one year and is observationally associated with dose-dependent cardiometabolic worsening.

• Adverse gastrointestinal event burden and treatment discontinuation. GI adverse events are the predominant tolerability concern across GLP-1 RA agents. In a real-world cohort of 10,328 adults, abdominal pain (57.6%), constipation (30.4%), diarrhea (32.7%), and nausea and vomiting (23.4%) were among the most common events. Meta-analyses of semaglutide in non-diabetic patients confirm that treatment discontinuation due to adverse events was significantly higher in the semaglutide group (RR 2.62, 95% CI: 1.70–4.03; P = .001). For tirzepatide, serious GI events and discontinuation due to adverse events carried relative risks of 3.07 (95% CI: 2.03–4.66) and 2.29 (95% CI: 1.74–3.01), respectively. Discontinuation rates can be up to 80% after 2 years across GLP-1 RA use broadly.

• Unfavorable body composition changes during pharmacotherapy. Pharmacotherapy-induced weight loss is not compositionally equivalent to exercise-induced loss. Lean mass losses averaging 6–7 kg and reductions in bone mineral density are seen during active incretin-based treatment, creating a metabolically unfavorable state at cessation compounded by fat-preferential regain. Up to 33% of the weight lost with GLP-1 RAs is lean tissue mass (muscle and bone), with downstream implications for resting metabolic rate and post-cessation rebound.

• Pre-existing micronutrient deficiencies complicating bariatric surgery candidacy. Patients with severe obesity frequently present with significant nutritional deficits prior to surgical intervention. In one cross-sectional study of bariatric candidates approved for Roux-en-Y gastric bypass, vitamin D deficiency was present in 92.9% and iron deficiency in 36.2–56.9% of participants. Multiple micronutrient deficiency was more common in Black patients (50.0% versus 39.7% overall). These pre-operative deficiencies are often undiagnosed and are correlated with adverse surgical outcomes.

• Long-term nutritional complications following bariatric surgery. Bariatric procedures introduce persistent risks of nutritional deficiency and GI dysfunction that extend well beyond the perioperative period. Post-operative complications include dumping syndrome, reactive hypoglycaemia, alopecia, and deficiencies in thiamine, iron, and vitamins — with thiamine deficiency capable of precipitating serious neurological sequelae such as Wernicke's encephalopathy and polyneuropathy. In one post-operative cohort, alopecia was reported in 79.3% of patients and dumping episodes in 65.5%, while GI tract changes were described in 86.2%.

• Metabolic efficiency as a predictor of weight regain after caloric restriction. Individual variability in 24-hour energy expenditure (24hEE) during eucaloric, sedentary conditions predicts the magnitude of weight regain following caloric restriction-induced weight loss. A relatively higher 24hEE by 100 kcal/day prior to caloric restriction was associated with an average greater rate of weight regain by +0.3 kg/month during follow-up and a greater final weight regain by +5.1 kg after 1 year of follow-up, underscoring the biological complexity of sustained weight loss maintenance.

Unlocking ALK7: A Novel Target for Obesity and Metabolic Health

Recent research has expanded the landscape of obesity therapeutics well beyond traditional appetite suppression, identifying multiple mechanistic axes — from gut-brain hormonal signaling to mitochondrial bioenergetics — as actionable targets. The following highlights represent distinct emerging and novel directions supported by current literature.

• GLP-1 Receptor Agonists and Polyagonists: Semaglutide and liraglutide are FDA- and EMA-approved GLP-1 receptor agonists for weight loss. Network meta-analysis of 27 randomized controlled trials (15,584 patients) found retatrutide 12 mg and retatrutide 8 mg produced the greatest body weight reductions (-22.10% and -20.70%, respectively) and waist circumference reductions (-17.00 cm and -15.90 cm) versus placebo among seven agents evaluated.

• Dual GLP-1/GIP Receptor Co-agonism (Tirzepatide): Tirzepatide, the first approved dual GLP-1/GIP receptor co-agonist, achieved body weight reductions of 16.5% to 22.4% over 72 weeks in people without diabetes (SURMOUNT-1), and a placebo-subtracted weight reduction of 17.8% in a 72-week randomized controlled trial. One source notes tirzepatide has demonstrated a 23% body weight reduction in individuals with obesity over 72 weeks, described as eclipsing the average result achieved by certain types of bariatric surgery.

• Triple GLP-1R/GIPR/GCGR Agonism (Retatrutide and Novel Triagonists): Retatrutide (LY3437943) simultaneously activates GLP-1, GIP, and glucagon receptors, achieving a placebo-subtracted weight reduction of -22.1% in a 48-week phase 2 trial, with one source noting approximately 25% body weight loss potentially surpassing the efficacy of Roux-en-Y gastric bypass. Rational design of novel xGLP-1-based triagonists — including xGLP/GCG/GIP-32, featuring potent GLP-1R and GCGR activity with weaker GIPR activation — has shown superior weight loss effects compared to tirzepatide and similar metabolic efficacy to retatrutide, suggesting that potent activation of all three receptors simultaneously may not be imperative, and that receptor-biased agonism warrants further exploration.

• GDF15–GFRAL Axis: Growth differentiation factor 15 (GDF15), acting through its CNS receptor GFRAL expressed on neurons in the hindbrain area postrema (AP) and nucleus of the solitary tract (NTS), plays a role in resistance to diet-induced obesity. Neutralization of endogenous GDF15 by monoclonal antibody in high-fat diet-fed mice resulted in more rapid body weight gain, increased adiposity, hepatic lipid deposition, reduced glucose and insulin tolerance, and greater pro-inflammatory cytokine expression in adipose tissue. Separately, red ginseng (RGS) was found to enrich Akkermansia muciniphila, whose derived protein Amuc_1631 promotes GDF15 secretion; RGS upregulated colonic Gdf15 transcription via the PERK-eIF2α-ATF4-CHOP axis and activated the brainstem GDF15-GFRAL pathway to suppress appetite and reduce body weight in diet-induced obese mice.

• Y4 Receptor Agonism: The novel Y4 receptor agonist BVD-74D significantly decreased cumulative food intake, water intake, and body weight gain in C57BL/6J mice on normal diet, and reduced food intake in mice on high-fat diet and in FLS-ob/ob mice, identifying the Y4 receptor as a promising target for obesity.

• Mitochondrial Uncoupling and Adaptive Thermogenesis: Increasing energy expenditure via mitochondrial uncoupling — disconnecting electron transport and oxygen consumption from ATP synthesis — represents a distinct therapeutic strategy. Ectopic expression of UCP1 in white adipose tissue produced robust obesity resistance and improved lipid metabolism in transgenic mice. Silencing of HIF3A in differentiating adipocytes promoted "browning" of white adipocytes, activating thermogenesis through upregulation of Ucp1, Elovl3, Prdm16, Dio2, and Ppargc1a genes, with Seahorse analysis showing significant increases in mitochondrial uncoupling and acetyl-CoA metabolism. Novel arylamide-substituted fatty acid protonophores — specifically 3,4-disubstituted arylamides — increased cellular respiration and partially depolarized mitochondria without compromising ATP production or cell viability, representing a framework for mild uncoupling agents that circumvent the toxicity of classical uncouplers. Carbon monoxide (CO)-based pharmacology has also emerged as a candidate approach, with experimental studies suggesting CO modulates mitochondrial bioenergetics, induces mild mitochondrial uncoupling, and regulates mitochondrial biogenesis.

• Brown and Beige Adipose Tissue Activation: BAT thermogenesis, regulated by the sympathetic nervous system via lipolysis and mitochondrial uncoupling in brown adipocytes, is an established emerging target. Novel central regulators identified include irisin, bone morphogenetic proteins (BMP7 and BMP8B), orexins, and the canonical ventromedial nucleus of the hypothalamus (VMH) AMPK-SNS-BAT axis. In human beige adipocytes, uncoupling capability has been demonstrated without UCP1 activity, opening a direction in drug discovery independent of UCP1. ATP-consuming futile cycles — including the lipolysis/fatty acid re-esterification cycle, creatine/phosphocreatine cycle, and SERCA-mediated calcium cycle — represent additional non-uncoupling energy dissipation mechanisms under investigation.

• Amylin Receptor Agonism and Combination Approaches: Cagrilintide, an amylin receptor agonist, has demonstrated substantial weight reduction in clinical trials both alone and in combination with semaglutide (CagriSema), representing a synergistic gut- and pancreas-hormone-based combination strategy.

The Race for Novel Obesity Mechanisms: Beyond Incretins

Three mechanistic classes dominate the investigational obesity pipeline beyond approved agents: amylin/calcitonin receptor agonism, multi-receptor incretin co-agonism (including glucagon receptor engagement), and oral small-molecule GLP-1 receptor agonism.

• Amylin and Calcitonin Receptor Agonism: Several long-acting amylin analogues are advancing in clinical development, including cagrilintide (a dual amylin and calcitonin receptor agonist, or DACRA), eloralintide (a selective AMY1R agonist), petrelintide, Met-233, and AZD6234. Eloralintide demonstrated clinically meaningful, dose-dependent bodyweight reductions over 48 weeks in a phase 2 trial, with the 9 mg dose achieving a mean percent change in bodyweight of -20% versus -0.4% for placebo. Cagrilintide has also been co-formulated with semaglutide (CagriSema), which in the REDEFINE 1 phase 3a trial achieved the greatest proportion of participants reaching BMI < 27 kg/m² and WHtR < 0.53 targets (30.3%) versus semaglutide (19.1%), cagrilintide (9.0%), or placebo (3.3%). Amycretin, a unimolecular AMYR/CTR/GLP-1R multi-agonist, is in development for both weekly injection and once-daily tablet formulations.

• Triple GLP-1/GIP/Glucagon Receptor Agonism: Retatrutide, a novel triple receptor agonist targeting GCGR, GIPR, and GLP-1R, has demonstrated average weight loss of 17.5% and 24.4% at 24 and 48 weeks, respectively, in phase 2 clinical trials. Its phase 3 trial for obesity, type 2 diabetes, and non-alcoholic fatty liver disease commenced on August 28, 2023. Efocipegtrutide is another agent in this triple agonist class. These agents overcome the limitations of single-target appetite suppression by synergistically integrating central anorexigenic signaling with peripherally mediated increases in energy expenditure. Dual GLP-1/glucagon co-agonists such as survodutide and mazdutide also fall within this broader mechanistic category and have demonstrated significant weight loss and improved glycemic control in trials.

• Oral Small-Molecule GLP-1 Receptor Agonism: Orforglipron and danuglipron are orally active small-molecule GLP-1 receptor agonists resistant to enzymatic degradation, representing a major advance in patient-friendly drug delivery. Orforglipron has reported approximately -15% weight reduction and is among 14 ongoing phase 3 trials in the investigational obesity pipeline. Oral semaglutide 50 mg is the only agent in this broader oral GLP-1 category to have completed a phase 3 trial to date. Completed phase 2 trials on incretin-based therapies across the pipeline have shown a mean percent weight loss ranging from 7.4% to 24.2%.

Roche's ALK7 Bet: A New Frontier in Obesity Treatment

Roche's latest licensing agreement for an experimental RNA interference (RNAi) medicine targeting the ALK7 protein for obesity marks a significant strategic maneuver in the rapidly expanding metabolic disease market. This move is not merely an addition to Roche's pipeline; it represents a calculated effort to diversify its approach beyond the increasingly crowded incretin-based therapy space, where it already has existing assets.

The scientific rationale behind targeting ALK7 is compelling. Research indicates that ALK7, also known as ACVR1C, is a key regulator of metabolic homeostasis, with studies showing that its loss-of-function or silencing can lead to beneficial metabolic outcomes. These include resistance to high-fat diet-induced obesity, increased fat utilization, improved insulin sensitivity, and reduced hyperlipidemia. Human genetic studies further bolster this target's validity, demonstrating that rare loss-of-function variants in ACVR1C correlate with a favorable body fat distribution and protection from type 2 diabetes and cardiovascular disease. By leveraging RNAi technology, Roche aims for a precise intervention, potentially offering a highly targeted therapy that could complement existing treatments or provide a novel option for patients who do not respond optimally to current standards of care.

However, this strategic play is not without its considerations. While ALK7 loss-of-function appears generally tolerated, the protein is expressed in various tissues and has been implicated in other biological processes, including cancer progression and metastasis. This raises questions about potential off-target effects or long-term safety implications that will need rigorous evaluation during clinical development. Furthermore, the obesity market is fiercely competitive, with a growing array of highly effective incretin agonists and other novel mechanisms emerging. For Roche's ALK7 RNAi to carve out a significant niche, it will need to demonstrate a superior efficacy profile, a distinct safety advantage, or the ability to address specific unmet needs within the diverse obesity patient population.